ALL09 - Phase II Study of Blinatumomab as Induction Therapy in Adolescent and Young Adult Acute Lymphoblastic Leukaemia
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms The SUBLIME Study
- 24 Sep 2019 Status changed from not yet recruiting to recruiting.
- 03 Aug 2019 Planned initiation date changed from 1 Mar 2019 to 17 Sep 2019.
- 30 Oct 2018 New trial record